hotspot -WSS

hotspot

author：comprehensive 2025-09-29 16:33:06 - browse：98

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

Fresh off of the news that its drug Wegovy may not just help people lose weight, but could also lower cardiac risks, Novo Nordisk doubled down on its obesity drug pipeline Thursday, acquiring a small Canadian biotech with a new approach to weight loss.

Novo will spend up to $1 billion to buy Inversago Pharma, which is developing an oral obesity drug that targets the cannabinoid receptor CB1. It’s the second big obesity acquisition this year, following Eli Lilly’s move to purchase startup Versanis Bio.

Drugs like Wegovy are in a class called GLP-1 drugs, which mimic the effects of the glucagon-like peptide 1 hormone that help people feel full by targeting the hormone’s receptors.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： U.K. Biobank has 500,000 peoples' genome sequences available

WSS

Readout Newsletter: Vertex, Pfizer, Kura, and other biotech news

What don’t we know about an Alzheimer’s drug side effect?

How to pay for weight loss drugs and save Medicare

Cigna, Humana reportedly in talks to merge

Rep. Raul Ruiz on the physician shortage and more

Biogen walks away from Aduhelm, years after polarizing approval

knowledge

hotspot

explore

Trump demands the U.S. pay no more for drugs than other countries … again

Health Care Service Corp to buy Cigna Medicare Advantage plans

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

30 years of 'Listening to Prozac'

In age of alternative facts, a scholarly course on calling out crap

Why you shouldn’t ask, “What country has the best health care?”

Medical leaders decry Supreme Court decision on affirmative action

Philips to halt sales of sleep apnea machines in U.S.

Duchenne breakthrough therapy leaves behind pioneering families

CDC director unscathed in first congressional testimony

explore

Despite FDA concern, risk that CAR

What to do when lifesaving products contribute to climate change

The latest on Bluebird gene therapies, Vertex's pain drug, and ADC FOMO

Cigna, Humana reportedly in talks to merge

As biotech industry slumps, bioscience job market is upside down

Boston competes with Raleigh

Wikipedia

focus

focus

hotspot